Cabaletta Bio Inc (CABA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cabaletta Bio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.70 $ — 48% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 395.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.34 | -1.64 – -1.00 | 0 | 36.3% | 5 |
| 12/31/2027 | -1.42 | -2.63 – -0.80 | 0 | -6.1% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.37 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.20 | – | 2 | -59.20 | -1,989.40 | -23 | -24 |
| 2025: Q1 | -0.22 | – | 0 | – | – | -31 | -32 |
| 2025: Q2 | -0.28 | – | 0 | – | – | -30 | -31 |
| 2025: Q3 | -0.28 | – | 0 | – | – | -35 | -35 |
| 2025: Q4 | -0.26 | – | 0 | -100.00 | – | -35 | -36 |
| 2026: Q1 | -0.27 | – | 0 | – | – | -43 | -43 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | – | 0 | 0 | -0.01 | -5 | 0 | 0 |
| 2018 | 0 | -6 | -12 | -0.84 | -5 | -11 | 34 |
| 2019 | 0 | -19 | -15 | -2.76 | -16 | 138 | 141 |
| 2020 | 0 | -34 | -32 | -1.40 | -27 | 110 | 115 |
| 2021 | 0 | -46 | -46 | -1.77 | -34 | 118 | 126 |
| 2022 | 0 | -54 | -52 | -1.77 | -46 | 105 | 117 |
| 2023 | 0 | -75 | -68 | -1.65 | -54 | 236 | 254 |
| 2024 | 0 | -125 | -116 | -2.34 | -88 | 152 | 185 |
| 2025 | 0 | -172 | -168 | -1.64 | -131 | 112 | 165 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Cabaletta Bio, Inc., ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entdeckung und Entwicklung gentechnisch veränderter T-Zell-Therapien für Patienten mit Autoimmunerkrankungen.
| Employees | 156 |
|---|---|
| Headquarters | Philadelphia, PA |
| Address | 2929 Arch Street, 19104 Philadelphia, United States |
| Phone | 267 759 3100 |
| Website | cabalettabio.com |
| IPO Date | 25. Oct 2019 |
| ISIN | US12674W1099 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven A. Nichtberger M.D. | Co-Founder, Chairman, CEO & President | 1961 |
| David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer | 1963 |
| Gwendolyn K. Binder Ph.D. | President of Science & Technology | 1975 |
| Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | – |
| Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | – |
| Anup Marda M.B.A. | Chief Financial Officer | 1978 |
| Qing Sarah Yuan Ph.D. | Chief Technology Officer | 1971 |
| Samik Basu M.D. | Chief Scientific Officer | – |
| Michael Gerard J.D. | General Counsel & Secretary | 1980 |
| Heather Harte-Hall M.Sc. | Chief Compliance Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.